{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T12:30:00Z","timestamp":1789907400208,"version":"4.0.1"},"reference-count":18,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100018822","name":"Western Sydney University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018822","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Pharmacological Sciences"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.tips.2026.01.009","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T13:35:31Z","timestamp":1771853731000},"page":"244-247","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Evolving paradigms in targeting FLT3 for acute myeloid leukemia therapy"],"prefix":"10.1016","volume":"47","author":[{"given":"Rajan","family":"Thapa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus","family":"Shrestha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keshav Raj","family":"Paudel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tips.2026.01.009_bb0005","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.3390\/cancers14143398","article-title":"\u201cFLipping\u201d the story: FLT3-mutated acute myeloid leukemia and the evolving role of FLT3 inhibitors","volume":"14","author":"Knight","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.tips.2026.01.009_bb0010","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/cas.14274","article-title":"FLT3 mutations in acute myeloid leukemia: therapeutic paradigm beyond inhibitor development","volume":"111","author":"Kiyoi","year":"2020","journal-title":"Cancer Sci."},{"key":"10.1016\/j.tips.2026.01.009_bb0015","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s12185-022-03374-0","article-title":"FLT3-targeted treatment for acute myeloid leukemia","volume":"116","author":"Arai","year":"2022","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.tips.2026.01.009_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104424","article-title":"Understanding mechanisms of resistance to FLT3 inhibitors in adult FLT3-mutated acute myeloid leukemia to guide treatment strategy","volume":"201","author":"Ruglioni","year":"2024","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.tips.2026.01.009_bb0025","article-title":"Resistance to FLT3 inhibitors involves different molecular mechanisms and reduces new DNA synthesis","volume":"41","author":"Yang","year":"2025","journal-title":"Biochem. Biophys. Rep."},{"key":"10.1016\/j.tips.2026.01.009_bb0030","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1158\/1535-7163.MCT-21-0317","article-title":"The irreversible FLT3 inhibitor FF-10101 is active against a diversity of FLT3 inhibitor resistance mechanisms","volume":"21","author":"Ferng","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.tips.2026.01.009_bb0035","doi-asserted-by":"crossref","first-page":"6191","DOI":"10.1182\/blood-2022-170445","article-title":"BMF-500: an orally bioavailable covalent inhibitor of FLT3 with high selectivity and potent antileukemic activity in FLT3-mutated AML","volume":"140","author":"Law","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.tips.2026.01.009_bb0040","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1186\/s12964-024-01729-0","article-title":"Ningetinib, a novel FLT3 inhibitor, overcomes secondary drug resistance in acute myeloid leukemia","volume":"22","author":"Hu","year":"2024","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.tips.2026.01.009_bb0045","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1696229","article-title":"Acute myeloid leukemia drug resistance: targetable nodes and the clinical trajectory of small-molecule inhibitors","volume":"16","author":"Zhang","year":"2025","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.tips.2026.01.009_bb0050","article-title":"Current therapeutic strategies for FLT3-mutated acute myeloid leukemia: a narrative review","volume":"17","author":"Swanson","year":"2025","journal-title":"Cureus"},{"key":"10.1016\/j.tips.2026.01.009_bb0055","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1038\/s41375-024-02405-5","article-title":"Selective degradation of mutant FMS-like tyrosine kinase-3 requires BIM-dependent depletion of heat shock proteins","volume":"38","author":"Halilovic","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.tips.2026.01.009_bb0060","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/s41375-024-02510-5","article-title":"Effective eradication of acute myeloid leukemia stem cells with FLT3-directed antibody-drug conjugates","volume":"39","author":"Able","year":"2025","journal-title":"Leukemia"},{"key":"10.1016\/j.tips.2026.01.009_bb0065","doi-asserted-by":"crossref","first-page":"7197","DOI":"10.1021\/acs.jmedchem.4c00051","article-title":"Discovery of a novel orally bioavailable FLT3-PROTAC degrader for efficient treatment of acute myeloid leukemia and overcoming resistance of FLT3 inhibitors","volume":"67","author":"Wang","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tips.2026.01.009_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115974","article-title":"Discovery of LWY713 as a potent and selective FLT3 PROTAC degrader with in vivo activity against acute myeloid leukemia","volume":"264","author":"Liu","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.tips.2026.01.009_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107477","article-title":"Discovery of a potent gilteritinib-based FLT3-PROTAC degrader for the treatment of acute myeloid leukemia","volume":"149","author":"Ye","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.tips.2026.01.009_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117893","article-title":"Discovery of degrader for FLT3, GSPT1 and IKZF1\/3 proteins merging PROTAC and molecular glue targeting FLT3-ITD mutant acute myeloid leukemia","volume":"296","author":"Yang","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.tips.2026.01.009_bb0085","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1182\/blood.2021015246","article-title":"Targeting FLT3 with a new-generation antibody-drug conjugate in combination with kinase inhibitors for treatment of AML","volume":"141","author":"Roas","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.tips.2026.01.009_bb0090","article-title":"FLT3L-based drug conjugate effectively targets chemoresistant leukemia stem cells in acute myeloid leukemia","volume":"6","author":"Zhang","year":"2025","journal-title":"Cell Rep. Med."}],"container-title":["Trends in Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614726000131?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614726000131?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T20:52:04Z","timestamp":1777495924000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165614726000131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0165614726000131"],"URL":"https:\/\/doi.org\/10.1016\/j.tips.2026.01.009","relation":{},"ISSN":["0165-6147"],"issn-type":[{"value":"0165-6147","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evolving paradigms in targeting FLT3 for acute myeloid leukemia therapy","name":"articletitle","label":"Article Title"},{"value":"Trends in Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tips.2026.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}